The Future of Pharmacogenomics in Everyday Pharmacy Practice

Pharmacogenomics is moving from a specialist discussion into the practical world of medication review, prescribing support and patient counselling. It examines how inherited genetic differences influence the way a person absorbs, metabolises or responds to medicines. For pharmacists, that means a future in which the right medicine is considered alongside the right dose, formulation, indication and patient history.

The technology is already relevant to several familiar clinical problems. Genetic variation can affect responses to antidepressants, antiplatelet medicines, anticoagulants, analgesics and selected treatments for cancer or neurological conditions. A test will not replace a complete medication history or professional judgement, but it may help explain treatment failure, adverse effects or an unusual dose requirement.

Australian pharmacy practice is well placed to contribute to this development. Pharmacists are accessible in metropolitan and regional communities, increasingly involved in medication reviews, and accustomed to translating complex clinical information into clear advice. The challenge is to ensure that pharmacogenomic information becomes clinically useful rather than another result added to an already crowded digital record.

The coming years will therefore be shaped by implementation as much as by laboratory science. Questions about evidence, consent, privacy, cost, prescriber communication and health equity will determine whether personalised medicine earns a place in routine dispensing and patient care across Australia.

From Specialist Test To Dispensing Decision

A pharmacogenomic result is valuable only when it changes a clinical decision. A report stating that a patient is a rapid metaboliser of a medicine may suggest a higher likelihood of reduced exposure, while another result may indicate increased sensitivity or a greater risk of toxicity. The pharmacist’s role is to interpret that information alongside age, kidney and liver function, pregnancy status, comorbidities, adherence and concurrent medicines.

This is different from using genetics as a shortcut. A patient’s DNA does not reveal whether they are taking a medicine correctly, whether an infection has altered their response, or whether a treatment is clinically appropriate in the first place. Pharmacogenomics adds another layer to medication safety. It can support a discussion with the prescriber, identify a need for monitoring or point towards an alternative, but it does not make an automatic prescribing decision.

The most useful results will be those linked to recognised clinical guidelines and clear action statements. Pharmacists may increasingly see reports that classify a patient’s phenotype and explain whether standard dosing, closer monitoring or an alternative medicine should be considered. This format is more practical than a raw genetic variant because it connects laboratory data with a dispensing decision.

Why Australian Practice Is Ready For Change

Australia has a strong network of community pharmacies, yet access to specialist services remains uneven. A patient in inner Melbourne may have several pathology providers and hospital clinics nearby, while someone in regional Queensland, northern Western Australia or Tasmania may face long travel for specialist review. Telehealth and digital referral pathways could help integrate pharmacogenomic testing into care, particularly when local pharmacists can coordinate follow-up and explain results.

The expansion of telepharmacy access offers a useful model for reaching communities where clinical resources are limited. Remote consultations cannot solve every issue, especially where pathology collection or reliable internet access is difficult, but they may connect rural patients with pharmacists, prescribers and genetic specialists. Pharmacists will need workflows that distinguish a genuine clinical need from tests marketed directly to consumers.

The Australian market also presents practical funding questions. Many pharmacogenomic tests are paid for privately, and access may depend on a patient’s income, private insurance or participation in a research program. They are not uniformly covered through the Pharmaceutical Benefits Scheme. In a healthcare system that values universal access, pharmacy leaders will need to consider whether testing is being offered to patients most likely to benefit or simply to those who can afford it.

Building Pharmacogenomics Into Pharmacy Workflow

The first step is likely to be targeted rather than universal testing. A pharmacist might identify a patient who has experienced several unexplained adverse effects, failed multiple medicines within the same therapeutic class or requires an unusual dose. A structured medication review could prompt a discussion with the prescriber about whether a pharmacogenomic assessment is clinically justified.

Documentation will be essential. The record should identify the test performed, the laboratory, the date, the relevant result, its interpretation and any action taken. Genetic information may remain relevant for many years, even when the original medicine is discontinued. Recording it in a way that can be found during future dispensing or hospital admission may prevent repeated testing and reduce the risk of overlooking an important result.

Interoperability will determine whether this information is genuinely useful. Results may arrive by secure email, laboratory portal, scanned document or a patient-held report, while dispensing data sit in a separate pharmacy system and clinical information may be stored in My Health Record. Clear consent processes and reliable data transfer will be needed before pharmacogenomics can operate smoothly across community pharmacies, general practices and hospitals.

Professional governance must develop alongside the technology. Pharmacists should know the limits of a test, recognise when a result is inconclusive and avoid presenting genetic risk as certainty. Local protocols can specify who reviews the report, how prescribers are contacted, when follow-up occurs and how patients are referred to a genetic counsellor or specialist.

Communicating Results With Patients

Genetic information can sound more definitive than it really is. Patients may hear that they have a “bad gene” or believe that a test predicts whether a medicine will work. A careful conversation should explain that most results indicate probability, not destiny. The result describes one factor influencing treatment response, while the person’s broader health, environment, other medicines and daily routine remain important.

Consent should cover the purpose of the test, the medicines it may inform, possible limitations and the handling of the data. Patients may have concerns about privacy, family implications or future use of their genetic information. Pharmacists do not need to provide specialist genetic counselling for every discussion, but they should be able to explain why the test is being considered and identify when a more specialised service is appropriate.

Language and cultural safety matter in Australia’s diverse communities. Genetic services should be accessible to Aboriginal and Torres Strait Islander peoples through respectful, community-informed approaches rather than assuming that a standard metropolitan model will fit every setting. Interpreters, culturally safe communication and time for shared decision-making can be as important as the test itself.

Pharmacists can also help patients distinguish clinically validated testing from broad commercial panels that promise personalised health insights. A test that examines dozens of genes is not automatically more useful than a targeted test connected to a specific medicine. The central question is whether the result is supported by evidence and whether a qualified clinician can act on it.

Evidence, Education And Sustainable Use

The evidence base is strongest where a genetic result has a well-established relationship with medicine exposure, treatment response or serious adverse reactions. It is less consistent for many complex conditions, where multiple genes and non-genetic factors contribute to outcomes. Pharmacists should therefore assess the quality of the laboratory, the guideline used and the relevance of the result to the patient’s current treatment.

Education will need to move beyond a single university lecture or optional professional development session. Pharmacy students and practising pharmacists require familiarity with genetic terminology, clinical guidelines, consent, privacy and communication. Prescribers, nurses and pathology professionals also need shared expectations so that pharmacogenomic recommendations do not become fragmented across the healthcare team.

A practical learning framework can help pharmacy teams prepare:

Useful capabilities

• Recognise medicines and patients for which testing may be relevant
• Interpret phenotype-based reports without overstating certainty
• Document results and communicate recommendations clearly
• Arrange follow-up after a treatment change

Cost-effectiveness will be another major consideration. Testing may be worthwhile when it prevents a serious adverse reaction, avoids repeated treatment failure or guides a medicine likely to be used for many years. It may be less valuable when the result will not change management. Health services and researchers will need Australian data on hospital admissions, medicine costs, patient outcomes and workforce time.

Questions for local services

• Who pays for testing and follow-up consultations?
• Which laboratory and clinical guidelines are trusted?
• How will results move between pharmacy, general practice and hospital care?
• How will access be monitored across metropolitan and rural communities?

Pharmacy organisations can support responsible adoption by developing practice standards, sample documentation and referral pathways. Research partnerships with universities, hospitals and primary care networks could also test models in real settings rather than assuming that an approach developed overseas will transfer directly to Australia.

The Role Of Pharmacists In The Next Decade

The pharmacist of the future may encounter pharmacogenomic information during a Home Medicines Review, a discharge reconciliation, a new antidepressant prescription or a conversation about repeated side effects. The role will involve recognising when a result matters, explaining it without alarm, and ensuring that it informs coordinated care. This is a natural extension of medication expertise rather than a replacement for medical or genetic specialists.

Antidepressant treatment illustrates the need for balanced interpretation. Genetic information may contribute to a discussion about metabolism or tolerability, but it does not remove the need to assess mood, suicide risk, psychosocial stressors, adherence and the patient’s preferences. Pharmacists can build on broader clinical knowledge, including guidance about new antidepressant formulations, while treating pharmacogenomics as one part of a complete therapeutic review.

In time, decision-support tools may flag relevant genetic results during prescribing or dispensing. Such systems could prompt a pharmacist to check a dose, contact a prescriber or arrange monitoring. They could also create new risks if alerts are poorly designed, based on weak evidence or displayed without clinical context. Human oversight will remain essential.

The strongest future model is collaborative. Pharmacists, GPs, psychiatrists, nurses, genetic counsellors, pathology providers and hospital teams each bring different expertise. When their communication is timely and patient-centred, pharmacogenomics can help make medicine use safer and more individualised without turning everyday practice into a laboratory exercise.

Pharmacy teams can begin preparing now by reviewing reliable clinical guidance, identifying suitable professional development and discussing data governance with their employers. Small pilots, careful documentation and honest conversations with patients will help build a service that is evidence-based, equitable and fit for Australian healthcare. Pharmacists who engage early can shape how personalised medicine is used at the counter, in consultation rooms and across the wider health system.